In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK's Virtual-Proof-of-Concept Unit in Tune with Lilly's Chorus

Executive Summary

Many readers will have heard of Eli Lilly's Chorus initiative, designed to drive compounds through to proof-of-concept as cheaply and quickly as possible. A less well-publicized but similar discovery-on-a-budget initiative is GlaxoSmithKline's VPoC--virtual-proof-of-concept--unit.

Related Content

Institutionalizing Externalization At Big Pharma – The Third Leg
Lilly Tries to Buy Time
GSK Tries to Mimic Real-World Biotech
Flexion: The In-Licensing Advantage of Cheap Proof-of-Concept
Lilly's Chorus Experiment
Lilly's Chorus Experiment


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts